Deintensified Chemoradiotherapy for Pretreatment Epstein-Barr Virus DNA-Selected Low-Risk Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase II Randomized Noninferiority Trial

Cumulative doses of 200 mg/m for concurrent cisplatin (DDP) were indicated by retrospective studies as sufficient in conferring survival benefit for locoregionally advanced nasopharyngeal carcinoma (LA-NPC). We performed an open-label, phase II, randomized, controlled trial to test the noninferiorit...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of clinical oncology 2022-04, Vol.40 (11), p.1163-1173
Hauptverfasser:	Li, Xiao-Yun, Luo, Dong-Hua, Guo, Ling, Mo, Hao-Yuan, Sun, Rui, Guo, Shan-Shan, Liu, Li-Ting, Yang, Zhen-Chong, Yang, Jin-Hao, Qiu, Fang, Sun, Xue-Song, Wang, Pan, Liu, Qing, Li, Ji-Bin, Tang, Qing-Nan, Lin, Chao, Yang, Qi, Liu, Sai-Lan, Liang, Yu-Jing, Jia, Guo-Dong, Wen, Dong-Xiang, Guo, Chun-Yan, Yan, Jin-Jie, Zhao, Chong, Chen, Qiu-Yan, Tang, Lin-Quan, Mai, Hai-Qiang
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Combined Chemotherapy Protocols - adverse effects Chemoradiotherapy - adverse effects Cisplatin DNA - therapeutic use Epstein-Barr Virus Infections Herpesvirus 4, Human - genetics Humans Nasopharyngeal Carcinoma - drug therapy Nasopharyngeal Neoplasms - pathology Neoplasm Recurrence, Local - drug therapy Quality of Life Retrospective Studies
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!